Search results for "Neoplasm Grading"

showing 8 items of 88 documents

Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression

2012

Wnt modulates glioma vascularization by regulating PDGF-B expression.

PathologyAngiogenesisCentral Nervous System NeoplasmsMice0302 clinical medicineImmunology and AllergyWnt Signaling Pathwaybeta Catenin0303 health sciencesbiologyNeovascularization PathologicBrain NeoplasmsWnt signaling pathwayIntracellular Signaling Peptides and ProteinsForkhead Transcription FactorsGliomaProto-Oncogene Proteins c-sis3. Good healthmedicine.anatomical_structureBlood-Brain Barrier030220 oncology & carcinogenesiscardiovascular systemIntercellular Signaling Peptides and ProteinsFemalemedicine.medical_specialtyBeta-cateninEndotheliumImmunologyNotch signaling pathwayMice NudeWnt1 ProteinMural cellArticle03 medical and health sciencesGliomamedicineAnimalsHumansddc:610neoplasms030304 developmental biologyAdaptor Proteins Signal TransducingCalcium-Binding ProteinsMembrane Proteinsmedicine.diseaseXenograft Model Antitumor Assaysnervous system diseasesDKK1Cancer researchbiology.proteinEndothelium VascularNeoplasm Grading
researchProduct

Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas.

2013

Several authors have demonstrated an increased number of mitotic figures in breast cancer resection specimen when compared with biopsy material. This has been ascribed to a sampling artifact where biopsies are (i) either too small to allow formal mitotic figure counting or (ii) not necessarily taken form the proliferating tumor periphery. Herein, we propose a different explanation for this phenomenon. Biopsy and resection material of 52 invasive ductal carcinomas was studied. We counted mitotic figures in 10 representative high power fields and quantified MIB-1 immunohistochemistry by visual estimation, counting and image analysis. We found that mitotic figures were elevated by more than th…

Pathologymedicine.medical_specialtyMitotic indexTime FactorsTissue FixationBiopsyMitosisBreast NeoplasmsBiologyPathology and Forensic MedicineBreast cancerPredictive Value of TestsBiopsyCarcinomamedicineMitotic IndexHumansNeoplasm InvasivenessMetaphaseMitosisMastectomyCell Proliferationmedicine.diagnostic_testCarcinoma Ductal BreastReproducibility of ResultsCell cyclemedicine.diseaseImmunohistochemistryKi-67 AntigenMitotic FigureLinear ModelsFemaleNeoplasm GradingModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

2019

Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Study aim: To evaluate the impact of a previous radical prostatectomy (RP) on the outcome of 223Ra therapy in mCRPC patients. The primary prostate tumor left untreated could progress during 223Ra treatment. Materials and methods: mCRPC symptomatic patients treated with 223Ra were enrolled. Luteinizing Hormone-Releasing Hormone analogue was maintained. No other anticancer therapy was given. 223Ra was administered i.v. at the dose of 55 kBq/kg every 4 weeks for 6 cycles. Patients were stratified according to previous RP or not. Hematological toxicity w…

Radium-223Malemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic AgentsBone NeoplasmsSettore MED/24 - UrologiaPrimary tumor03 medical and health sciencesProstate cancer0302 clinical medicineProstateRadium-222medicineHumansAgedProstatectomyRadiotherapybusiness.industryProstatectomyProstateChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadical prostatectomyPrimary tumorSurvival AnalysisRadiation therapyProstatic Neoplasms Castration-Resistantmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisConcomitantDisease ProgressionCastration resistant prostate cancerNeoplasm GradingRadiopharmaceuticalsbusinessmedicine.drugHormoneFollow-Up StudiesRadiumUrologic oncology
researchProduct

Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: A systematic review

2013

AIM: To investigate potential therapeutic recommendations for endoscopic and surgical resection of T1a/T1b esophageal neoplasms. METHODS: A thorough search of electronic databases MEDLINE, Embase, Pubmed and Cochrane Library, from 1997 up to January 2011 was performed. An analysis was carried out, pooling the effects of outcomes of 4241 patients enrolled in 80 retrospective studies. For comparisons across studies, each reporting on only one endoscopic method, we used a random effects meta-regression of the log-odds of the outcome of treatment in each study. “Neural networks” as a data mining technique was employed in order to establish a prediction model of lymph node status in superficial …

medicine.medical_specialtyBrief ArticleEsophageal NeoplasmsLymphovascular invasionEndoscopic mucosal resectionRisk AssessmentRisk FactorsmedicineCarcinomaOdds RatioHumansNeoplasm InvasivenessLymph nodeNeoplasm Stagingbusiness.industryCarcinoma in situPatient SelectionCarcinomaGastroenterologyGeneral MedicineEsophageal cancermedicine.diseaseSurgerySquamous carcinomaEsophagectomymedicine.anatomical_structureTreatment OutcomeLymphatic MetastasisAdenocarcinomaRadiologyEsophagoscopyNeoplasm GradingNeoplasm Recurrence Localbusiness
researchProduct

A systematic review and meta-analysis comparing surgical and oncological outcomes of upper rectal, rectosigmoid and sigmoid tumours.

2021

Abstract Aim Management paradigms for tumours from the sigmoid colon to the lower rectum vary significantly. The upper rectum (UR) represents the transition point both anatomically and in treatment protocols. Above the UR is clearly defined and managed as colon cancer and below is managed as rectal cancer. This study compares outcomes between sigmoid, rectosigmoid and UR tumours to establish if differences exist in operative and oncological outcomes. Methods Electronic databases were searched for published studies with comparative data on peri-operative and oncological outcome for upper rectal and sigmoid/rectosigmoid (SRS) tumours treated without neoadjuvant radiation. The search adhered t…

medicine.medical_specialtyColorectal cancermedicine.medical_treatmentHealth StatusRectumAnastomotic LeakAnastomosis03 medical and health sciences0302 clinical medicinemedicineHumansNeoplasm MetastasisIntraoperative ComplicationsLymph nodeNeoplasm Stagingbusiness.industryRectal NeoplasmsRectumSigmoid colonCancerGeneral Medicinemedicine.diseaseRadiation therapySurvival RateSigmoid Neoplasmsmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisLymphatic Metastasis030211 gastroenterology & hepatologySurgeryRadiologyNeoplasm GradingNeoplasm Recurrence LocalbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Obesity, an independent predictor of pre and postoperative tumor grading disagreement in endometrial cancer

2021

Abstract Introduction Obesity is a known independent risk factor for endometrial cancer (EC), and obese patients have a 4.7-fold increased risk compared to the general population to develop the neoplasm. To date, a general pre and postoperative tumor grading agreement from 53 % to 82 % is reported for endometrial analysis, and a consensus on which factors might influence the tumor grading discordance is still absent. Furthermore, although obesity alters the endometrial microenvironment, no studies investigated the role of obesity in the grading agreement of EC patients. This study aims to analyze the role of obesity in the pre and postoperative tumor grading agreement. Materials and methods…

medicine.medical_specialtyMultivariate analysisBiopsyConcordancePopulationGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineTumor MicroenvironmentmedicineHumansObesity030212 general & internal medicineRisk factoreducationGrading (tumors)Retrospective Studieseducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryEndometrial cancerObstetrics and GynecologyCancerOdds ratiomedicine.diseaseEndometrial NeoplasmsReproductive MedicineFemaleNeoplasm GradingbusinessEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

2012

Item does not contain fulltext CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findi…

medicine.medical_specialtyUrologymedicine.medical_treatmentUrologyMEDLINEAntineoplastic AgentsContext (language use)Aetiology screening and detection [ONCOL 5]CystectomyQuality of Care [ONCOL 4]Molecular epidemiology [NCEBP 1]CystectomyTranslational research [ONCOL 3]medicineHumansNeoplasm InvasivenessProspective cohort studyNeoplasm StagingBladder cancermedicine.diagnostic_testbusiness.industryGeneral surgeryCarcinoma in situCystoscopymedicine.diseaseAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsBCG VaccineDisease ProgressionNeoplasm GradingNeoplasm Recurrence LocalUrotheliumbusinessIntravesical chemotherapyCarcinoma in SituEuropean Urology
researchProduct

Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.

2021

Abstract Introduction Renal cell carcinoma (RCC) accounts for 2–3% of all tumors being the most frequent solid lesion in the kidney. Objective To determine what genetic alterations and immunohistochemical (IHC) of clear cell renal carcinoma (ccRCC) are associated with prognosis and tumor aggressiveness. Patients and Methods Experimental analytical study with 57 patients who underwent radical and partial nephrectomy between 2005 and 2011, all with diagnosis of ccRCC and minimum post-operative follow-up of 36 months. The pathological study included IHC determination of biomarkers associated (CAIX, CAM 5.2, CD10, c-erbB-2, EGFR, HIF-1a, Ki67, MDM2, PAX-2 y 8, p53, survivin and VEGFR 1 and 2). …

p530301 basic medicineMaleCancer Researchmedicine.medical_treatmentGastroenterologyNephrectomy0302 clinical medicineFHITRenal cell carcinomaCDKN2ANeoplasm MetastasisClear cell renal carcinomaRC254-282KidneyBRCA1 y 2Neoplasms. Tumors. Oncology. Including cancer and carcinogensCDKN2A: cyclin-dependent kinase Inhibitor 2AMiddle AgedPrognosisImmunohistochemistryNephrectomyKidney NeoplasmsMLPATumor BurdenSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.medical_specialty03 medical and health sciencesInternal medicinemedicineHumansMultiplex ligation-dependent probe amplificationCarbonic Anhydrase IXSurvival rateCarcinoma Renal CellAgedNeoplasm Stagingbusiness.industryCAIXmedicine.disease030104 developmental biologyNeoplasm GradingNeoplasm Recurrence LocalbusinessTranscriptomeFollow-Up StudiesCancer treatment and research communications
researchProduct